Ranbaxy To Seek Indian Strategic Alliance With Orchid
This article was originally published in PharmAsia News
Instead of a rumored hostile takeover, Ranbaxy Group appears close to a strategic alliance with Orchid Chemicals & Pharmaceuticals. Solrex Pharmaceuticals, believed to be a Ranbaxy-promoted company, is not expected to increase its recently acquired 14.7 percent share in Orchid, which would have put its investment at the 15 percent threshold requiring it to offer to buy an additional 20 percent of shares. A Ranbaxy-Orchid strategic relationship is seen as beneficial to both since Orchid makes active pharmaceutical ingredients and Ranbaxy already has a strong position in U.S. markets. Neither firm would confirm the plan. (Click here for more
You may also be interested in...
ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.